Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Simon Property Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Simon Property Group Inc trades at $219.09 (market cap $73.68B). The key difference: Simon Property Group Inc is far larger — about 16.4× ACADIA Pharmaceuticals Inc.'s market cap, and Simon Property Group Inc pays a 3.87% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SPG | |
|---|---|---|
Market Cap | $4.49B | $73.68B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $227.56 |
52-Week Low | $20.06 | $159.93 |
Enterprise Value | $3.69B | $102.16B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Simon Property Group (SPG) trades at $227.19, up 0.5% on the day, with strong technical momentum as the stock approaches key resistance near $228. The REIT demonstrates robust fundamentals with Q1 2026 earnings beating expectations, revenue growth accelerating to $6.36B in 2025, and exceptional profitability metrics including 70.59% net income margin and 127.05% ROE. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering, while analyst sentiment remains mixed despite strong operational performance.
SPG presents a compelling investment case with premium mall assets generating strong cash flows and dividend income, though elevated valuation multiples and significant debt levels warrant caution. The stock's current price above the $211.30 consensus target suggests limited near-term upside, while e-commerce competition and interest rate sensitivity represent ongoing headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
